-
CSCO 2024 | Dr. Yongmei Yin: A New Era in HER2-Positive Breast Cancer Treatment—From Targeted Therapy to ADC Breakthroughs
With the rapid advancement of medical technology, the treatment of HER2-positive breast cancer has entered a new chapter. In recent years, the emergence of anti-HER2 targeted drugs and new ADC (Antibody-Drug Conjugates) drugs has not only enriched the treatment options but also brought unprecedented hope to patients with HER2-positive breast cancer. At CSCO 2024, Oncology…
-
CUA 2024丨Academician Xu Zhang Shares Conference Highlights and New Advances in Prostate Cancer Radioligand Therapy, and Looks Ahead at the Future Deve
The 31st Urology Academic Conference, organized by the Chinese Medical Association and the Chinese Urological Association (CUA), took place from September 19 to 22, 2024, at the National Convention Center in Tianjin. The conference brought together leading urology experts to showcase the latest clinical research and surgical advancements. After the event, Urology Frontier invited Academician…
-
ESMO 2024丨Dr. Liangyou Gu: Application and Development of Neoadjuvant Therapy in Renal Cancer with Venous Tumor Thrombus
The 2024 European Society for Medical Oncology (ESMO) Annual Meeting took place from September 13 to 17 in Barcelona, Spain. At the event, Dr. Liangyou Gu from the Urology Department of Chinese PLA General Hospital shared findings from the Phase II NEOTAX study on neoadjuvant therapy for renal cancer patients with venous tumor thrombus. The…
-
CSCO 2024 | Academician Binghe Xu: Advancing China’s Clinical Oncology Research with Innovative Drug Development
The 27th National Clinical Oncology Conference and 2024 CSCO Annual Meeting, jointly hosted by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Xisike Clinical Oncology Research Foundation, took place from September 25 to 29, 2024, in Xiamen. During this prestigious event, CSCO awarded Academician Binghe Xu with the “2024 Annual Achievement Award” in…
-
CSCO 2024 | Dr. Jian Zhang & Dr. Nadia Harbeck: East-West Collaboration on New Advances in Breast Cancer Treatment
As antibody-drug conjugates (ADCs) and precision medicine continue to develop, breast cancer is entering a new era of treatment. At the 2024 CSCO Annual Conference, Dr. Jian Zhang from Fudan University Shanghai Cancer Center and Dr. Nadia Harbeck from LMU University Hospital, Munich,Germany engaged in a deep discussion about the latest developments in breast cancer…
-
2024 CACA丨 How to Balance Hepatic Adjuvant Therapy? Dr. Minshan Chen Shares Advances and Strategies in Liver Cancer Adjuvant Treatment
Hepatology Digest: Could you discuss the evolution and clinical value of interventional therapy in postoperative adjuvant treatment for liver cancer? Dr. Minshan Chen: Interventional therapy is one method for preventing…
-
Dr. Shuihua Lu: Expanding from Tuberculosis-Free Communities to Tuberculosis-Free Cities with the Power of Technology丨15th Tuberculosis Eastern Forum
01 Infectious Diseases Frontier: Congratulations on the successful conclusion of the 15th Tuberculosis Eastern Forum! Could you introduce the history of the forum and the highlights of this year’s event?…
-
ESMO China’s Voice | Dr. Xiaojia Wang: Ivonescimab Dual PD-1/VEGF Blockade Achieves 72.4% ORR as a First-Line Therapy, Setting a New Standard for TNBC
The 2024 European Society for Medical Oncology (ESMO) Congress took place from September 13 to 17 in Barcelona, Spain. As one of the largest and most prestigious clinical oncology conferences in the world, it showcased numerous cutting-edge research findings, driving global advancements in oncology. In the field of breast cancer, Dr. Xiaojia Wang from Zhejiang…
Connecting Medical Expertise through Media